Phase 3 trial of Novavax investigational COVID-19 vaccine opens

(NIH/National Institute of Allergy and Infectious Diseases) The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine candidate developed by Novavax, Inc., of Gaithersburg, Maryland. Novavax is leading the trial as the regulatory sponsor. NIAID and BARDA are funding the trial.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news